[89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trial.

Autor: Adams, H., van de Garde, E. M. W., Vugts, D. J., Grutters, J. C., Oyen, Wim. J.G., Keijsers, R. G.

Publikováno v: European Journal of Nuclear Medicine & Molecular Imaging; Jun2023, Vol. 50 Issue 7, p1929-1939, 11p, 1 Color Photograph, 1 Diagram, 2 Charts, 3 Graphs

Application of ⁸⁹Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody.

Autor: Stergiou, N., Wuensche, T. E., Schreurs, M., Mes, I., Verlaan, M., Kooijman, E. J. M., Windhorst, A. D., Helboe, L., Vergo, S., Christensen, S., Asuni, A. A., Jensen, A., Van Dongen, G. A. M. S., Bang-Andersen, B., Vugts, D. J., Beaino, W.

Publikováno v: European Journal of Nuclear Medicine & Molecular Imaging; Apr2023, Vol. 50 Issue 5, p1306-1317, 12p, 3 Diagrams, 1 Chart, 3 Graphs

Corrigendum to 'SSP-27: 89Zr-immuno-PET of a novel bispecific amyloid β monoclonal antibody reveals improved and high specific brain uptake' [Nucl Med Biol (2020) Volumes 96–97, Supplement. S30-S31] (Nuclear Medicine and Biology (2021) 96–97(S) (S1–S114), (S0969805121X00042))

Autor: Stergiou, N., Wünsche, E. T., Mes, I., Schreurs, M., Verlaan, M., Kooijman, E. J. M., Windhorst, A. D., Dongen, G. A. M. S., Helboe, L., Vergo, S., Christensen, S., Asuni, A., Jensen, A., Bang-Andersen, B., Vugts, D. J., Beaino, W.

Publikováno v: Nuclear Medicine and Biology. Elsevier Inc.
Stergiou, N, Wünsche, E T, Mes, I, Schreurs, M, Verlaan, M, Kooijman, E J M, Windhorst, A D, Dongen, G A M S, Helboe, L, Vergo, S, Christensen, S, Asuni, A, Jensen, A, Bang-Andersen, B, Vugts, D J & Beaino, W 2021, ' Corrigendum to “SSP-27: 89Zr-immuno-PET of a novel bispecific amyloid β monoclonal antibody reveals improved and high specific brain uptake” [Nucl Med Biol (2020) Volumes 96–97, Supplement. S30-S31] (Nuclear Medicine and Biology (2021) 96–97(S) (S1–S114), (S0969805121X00042)) ', Nuclear Medicine and Biology . https://doi.org/10.1016/j.nucmedbio.2021.05.006

The authors regret . The authors would like to apologise for any inconvenience caused.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::31f8d957822e8ab24d242ee036768a2b
https://research.vumc.nl/en/publications/3f868859-8c02-4470-a3af-8806b2d6ce78

Correction to:[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2020), 47, 4, (849-859), 10.1007/s00259-019-04555-6)

Autor: van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C.T., Dekker, H., van Dongen, G. A.M.S., Vugts, D. J., Boellaard, R., van Herpen, C. M.L., de Vries, E. G.E., Oyen, W. J.G., Brouwers, A. H., Verheul, H. M.W., Hoekstra, O. S., der Houven van Oordt, C. W.Menke van

Publikováno v: van Helden, E J, Elias, S G, Gerritse, S L, van Es, S C, Boon, E, Huisman, M C, van Grieken, N C T, Dekker, H, van Dongen, G A M S, Vugts, D J, Boellaard, R, van Herpen, C M L, de Vries, E G E, Oyen, W J G, Brouwers, A H, Verheul, H M W, Hoekstra, O S & der Houven van Oordt, C W M V 2020, ' Correction to : [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2020), 47, 4, (849-859), 10.1007/s00259-019-04555-6) ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. 10, pp. 2481 . https://doi.org/10.1007/s00259-020-04908-6

The Electronic Supplementary Materials are missing in the original article. Kindly check the Electronic Supplementary Materials in this article. The Publisher regrets this error.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10172::0c0938e5110305b00cc0d60e8bed533c
https://research.vumc.nl/en/publications/0c4bd5ae-9627-44b4-9087-a375c3e76a80

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.